Previous close | 10.48 |
Open | 10.43 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 10.36 - 10.57 |
52-week range | 10.36 - 10.57 |
Volume | |
Avg. volume | N/A |
Market cap | 18.143M |
Beta (5Y monthly) | 0.33 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis treatment. The European Medicines Agency's (EMA) human medicines committee has recommended the drug's approval, setting up a challenge to the market-leading Dupixent, produced by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN).